EE9800315A - Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil - Google Patents

Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil

Info

Publication number
EE9800315A
EE9800315A EE9800315A EE9800315A EE9800315A EE 9800315 A EE9800315 A EE 9800315A EE 9800315 A EE9800315 A EE 9800315A EE 9800315 A EE9800315 A EE 9800315A EE 9800315 A EE9800315 A EE 9800315A
Authority
EE
Estonia
Prior art keywords
heart failure
treating heart
endothelin antagonists
blooded animal
warm blooded
Prior art date
Application number
EE9800315A
Other languages
English (en)
Estonian (et)
Inventor
J. Lynch Joseph Jr.
Shen You-Tang
Original Assignee
Banyu Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharmaceutical Co., Ltd. filed Critical Banyu Pharmaceutical Co., Ltd.
Publication of EE9800315A publication Critical patent/EE9800315A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
EE9800315A 1996-04-04 1997-03-19 Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil EE9800315A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1488296P 1996-04-04 1996-04-04
PCT/US1997/003737 WO1997037665A1 (en) 1996-04-04 1997-03-19 Method of treating heart failure with endothelin antagonists

Publications (1)

Publication Number Publication Date
EE9800315A true EE9800315A (et) 1999-06-15

Family

ID=21768326

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800315A EE9800315A (et) 1996-04-04 1997-03-19 Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil

Country Status (25)

Country Link
US (3) US5834483A (no)
EP (1) EP0906108B1 (no)
JP (2) JP3345891B2 (no)
KR (1) KR20000005178A (no)
CN (1) CN1215335A (no)
AT (1) ATE297739T1 (no)
AU (1) AU723351B2 (no)
BG (1) BG102716A (no)
BR (1) BR9708525A (no)
CA (1) CA2249330C (no)
CZ (1) CZ296098A3 (no)
DE (1) DE69733557T2 (no)
EA (1) EA003587B1 (no)
EE (1) EE9800315A (no)
ES (1) ES2241047T3 (no)
HU (1) HUP9903893A3 (no)
IL (1) IL126175A (no)
IS (1) IS4847A (no)
NO (1) NO984564L (no)
NZ (1) NZ331789A (no)
PL (1) PL329077A1 (no)
SK (1) SK130098A3 (no)
TR (1) TR199801988T2 (no)
UA (1) UA50761C2 (no)
WO (1) WO1997037665A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708525A (pt) * 1996-04-04 1999-08-03 Banyu Pharma Co Ltd Método de tratamento de insuficência cardíaca com antagonistas de endotelina
WO1998006700A1 (en) * 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
JP4432261B2 (ja) 1998-01-21 2010-03-17 萬有製薬株式会社 複素芳香環縮合シクロペンテノピリジン誘導体
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JPWO2004060885A1 (ja) * 2002-12-27 2006-05-11 株式会社カネカ 光学活性２−チオメチル−３−フェニルプロピオン酸誘導体およびその合成中間体の製造法
KR20180050427A (ko) 2003-11-17 2018-05-14 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1977741A3 (en) 2004-03-17 2009-10-14 Novartis AG Use of renin inhibitors in therapy
US20100040666A1 (en) 2005-06-24 2010-02-18 Hiroshi Azuma Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent
AR080683A1 (es) 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0714897B1 (en) * 1993-08-18 2001-02-14 Banyu Pharmaceutical Co., Ltd. Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
BR9708525A (pt) * 1996-04-04 1999-08-03 Banyu Pharma Co Ltd Método de tratamento de insuficência cardíaca com antagonistas de endotelina

Also Published As

Publication number Publication date
IL126175A (en) 2003-05-29
EP0906108B1 (en) 2005-06-15
EP0906108A1 (en) 1999-04-07
HUP9903893A2 (hu) 2001-04-28
JP2002220337A (ja) 2002-08-09
KR20000005178A (ko) 2000-01-25
EA003587B1 (ru) 2003-06-26
IL126175A0 (en) 1999-05-09
CZ296098A3 (cs) 1999-06-16
ES2241047T3 (es) 2005-10-16
TR199801988T2 (xx) 2000-08-21
UA50761C2 (uk) 2002-11-15
CN1215335A (zh) 1999-04-28
PL329077A1 (en) 1999-03-15
SK130098A3 (en) 1999-05-07
ATE297739T1 (de) 2005-07-15
AU723351B2 (en) 2000-08-24
US5834483A (en) 1998-11-10
US6380195B1 (en) 2002-04-30
CA2249330C (en) 2005-08-09
EA199800889A1 (ru) 1999-04-29
DE69733557T2 (de) 2005-11-03
JP3345891B2 (ja) 2002-11-18
BG102716A (en) 1999-09-30
IS4847A (is) 1998-09-15
NO984564L (no) 1998-12-04
CA2249330A1 (en) 1997-10-16
DE69733557D1 (de) 2005-07-21
US6087360A (en) 2000-07-11
JP2000510824A (ja) 2000-08-22
NO984564D0 (no) 1998-09-30
HUP9903893A3 (en) 2001-05-28
BR9708525A (pt) 1999-08-03
NZ331789A (en) 2000-05-26
EP0906108A4 (en) 2000-12-06
AU2202597A (en) 1997-10-29
WO1997037665A1 (en) 1997-10-16

Similar Documents

Publication Publication Date Title
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
CY1106046T1 (el) Μεθοδος για την θεραπευτικη αγωγη ινωσεως με χρησιμοποιηση ενος ανταγωνιστου της αλφα-4-υπομοναδος της ιντεγκρινης
HK1044333A1 (zh) 趨化因子受體拮抗劑及其使用方法
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
DE60101339D1 (de) Stimulierung des knochenwachstums mit peptidderivaten von thrombin
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
DE69637050D1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
DE69431601D1 (de) Neue verwendung von dexmedetomidin
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
PT1039900E (pt) Agentes terapeuticos
EA199900431A1 (ru) Способ профилактики рака молочной железы
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
HK1015708A1 (en) Use of muteins of wild-type cytokines as immunogens.